Juniper Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing therapeutics that address unmet medical needs in women's health. The company develops its products using its drug delivery technologies, including bioadhesive delivery system and a segmented intra-vaginal ring technology. It develops and markets five bioadhesive gel products, including CRINONE, a progesterone gel for use in infertility, which is marketed by Actavis, Inc. in the United States and by Merck Serono S.A. in approximately 60 countries worldwide. The company is also developing COL-1077, a 10% lidocaine bioadhesive gel intended as an acute use anesthetic for minimally invasive gynecological procedures. In addition, it provides pharmaceutical development, clinical trial supply manufacturing, and analytical services, as well as consultative services to its pharmaceutical industry customers. The company was formerly known as Columbia Laboratories, Inc. and changed its name to Juniper Pharmaceuticals, Inc. in April 2015. Juniper Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Boston, Massachusetts.